281 related articles for article (PubMed ID: 9395198)
1. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643.
Peters JM; Cattley RC; Gonzalez FJ
Carcinogenesis; 1997 Nov; 18(11):2029-33. PubMed ID: 9395198
[TBL] [Abstract][Full Text] [Related]
2. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats.
Marsman DS; Cattley RC; Conway JG; Popp JA
Cancer Res; 1988 Dec; 48(23):6739-44. PubMed ID: 3180084
[TBL] [Abstract][Full Text] [Related]
3. Induction of replicative DNA synthesis and PPAR alpha-dependent gene transcription by Wy-14 643 in primary rat hepatocyte and non-parenchymal cell co-cultures.
Karam WG; Ghanayem BI
Carcinogenesis; 1997 Nov; 18(11):2077-83. PubMed ID: 9395205
[TBL] [Abstract][Full Text] [Related]
4. Dietary glycine prevents increases in hepatocyte proliferation caused by the peroxisome proliferator WY-14,643.
Rose ML; Germolec D; Arteel GE; Schoonhoven R; Thurman RG
Chem Res Toxicol; 1997 Oct; 10(10):1198-204. PubMed ID: 9348444
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the hepatic effects of nafenopin and WY-14,643 on peroxisome proliferation and cell replication in the rat and Syrian hamster.
Lake BG; Evans JG; Cunninghame ME; Price RJ
Environ Health Perspect; 1993 Dec; 101 Suppl 5(Suppl 5):241-7. PubMed ID: 8013414
[TBL] [Abstract][Full Text] [Related]
6. Age-related susceptibility to the carcinogenic effect of the peroxisome proliferator WY-14,643 in rat liver.
Cattley RC; Marsman DS; Popp JA
Carcinogenesis; 1991 Mar; 12(3):469-73. PubMed ID: 1849052
[TBL] [Abstract][Full Text] [Related]
7. Increased nuclear ploidy, not cell proliferation, is sustained in the peroxisome proliferator-treated rat liver.
Lalwani ND; Dethloff LA; Haskins JR; Robertson DG; de la Iglesia FA
Toxicol Pathol; 1997; 25(2):165-76. PubMed ID: 9125775
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic effects of the continuous exposure to peroxisome proliferator WY-14,643 in mouse liver are dependent upon peroxisome proliferator activated receptor alpha.
Pogribny IP; Tryndyak VP; Woods CG; Witt SE; Rusyn I
Mutat Res; 2007 Dec; 625(1-2):62-71. PubMed ID: 17586532
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of the hepatocarcinogenesis caused by dehydroepiandrosterone, a peroxisome proliferator, in male F-344 rats.
Hayashi F; Tamura H; Yamada J; Kasai H; Suga T
Carcinogenesis; 1994 Oct; 15(10):2215-9. PubMed ID: 7955056
[TBL] [Abstract][Full Text] [Related]
10. Evidence that reduction of hepatocyte growth factor (HGF) is not required for peroxisome proliferator-induced hepatocyte proliferation.
Kiss A; Ortiz-Aguayo R; Sharp R; Merlino G; Thorgeirsson SS; Gonzalez FJ; Peters JM
Carcinogenesis; 2001 Jun; 22(6):975-9. PubMed ID: 11375907
[TBL] [Abstract][Full Text] [Related]
11. Effect on the expression of c-met, c-myc and PPAR-alpha in liver and liver tumors from rats chronically exposed to the hepatocarcinogenic peroxisome proliferator WY-14,643.
Miller RT; Glover SE; Stewart WS; Corton JC; Popp JA; Cattley RC
Carcinogenesis; 1996 Jun; 17(6):1337-41. PubMed ID: 8681452
[TBL] [Abstract][Full Text] [Related]
12. PPAR: a mediator of peroxisome proliferator action.
Green S
Mutat Res; 1995 Dec; 333(1-2):101-9. PubMed ID: 8538617
[TBL] [Abstract][Full Text] [Related]
13. Hepatic expression of acute-phase protein genes during carcinogenesis induced by peroxisome proliferators.
Anderson SP; Cattley RC; Corton JC
Mol Carcinog; 1999 Dec; 26(4):226-38. PubMed ID: 10569800
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis, mitosis and cyclophilin-40 expression in regressing peroxisome proliferator-induced adenomas.
Miller RT; Anderson SP; Corton JC; Cattley RC
Carcinogenesis; 2000 Apr; 21(4):647-52. PubMed ID: 10753199
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of hepatocarcinogenesis by the deletion of the p50 subunit of NF-kappaB in mice administered the peroxisome proliferator Wy-14,643.
Glauert HP; Eyigor A; Tharappel JC; Cooper S; Lee EY; Spear BT
Toxicol Sci; 2006 Apr; 90(2):331-6. PubMed ID: 16434500
[TBL] [Abstract][Full Text] [Related]
16. Differences between the promoting activities of the peroxisome proliferator WY-14,643 and phenobarbital in rat liver.
Cattley RC; Popp JA
Cancer Res; 1989 Jun; 49(12):3246-51. PubMed ID: 2566380
[TBL] [Abstract][Full Text] [Related]
17. Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisome proliferator, Wy-14,643.
Marsman DS; Popp JA
Carcinogenesis; 1994 Jan; 15(1):111-7. PubMed ID: 7507413
[TBL] [Abstract][Full Text] [Related]
18. Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid.
Marsman DS; Goldsworthy TL; Popp JA
Carcinogenesis; 1992 Jun; 13(6):1011-7. PubMed ID: 1600604
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis.
Peters JM; Rusyn I; Rose ML; Gonzalez FJ; Thurman RG
Carcinogenesis; 2000 Apr; 21(4):823-6. PubMed ID: 10753222
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883.
Eacho PI; Lanier TL; Brodhecker CA
Carcinogenesis; 1991 Sep; 12(9):1557-61. PubMed ID: 1893515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
